StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB - Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

A number of other research analysts also recently commented on the company. Chardan Capital reaffirmed a "neutral" rating and set a $6.00 target price (up previously from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. The Goldman Sachs Group dropped their price objective on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a research note on Friday, March 14th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $73.67.

Seres Therapeutics Trading Up 0.3%

Shares of Seres Therapeutics stock traded up $0.03 during trading on Friday, hitting $7.40. 49,226 shares of the stock traded hands, compared to its average volume of 147,406. Seres Therapeutics has a 52-week low of $6.64 and a 52-week high of $30.60. The stock's fifty day simple moving average is $11.38 and its 200 day simple moving average is $14.57. The firm has a market cap of $64.57 million, a P/E ratio of -32.15 and a beta of 2.89.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). As a group, equities analysts expect that Seres Therapeutics will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Seres Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC boosted its stake in Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 18,191 shares in the last quarter. Avantax Advisory Services Inc. increased its stake in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after buying an additional 28,500 shares during the period. Jane Street Group LLC raised its position in Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after buying an additional 37,866 shares during the last quarter. Northern Trust Corp increased its holdings in Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock valued at $218,000 after acquiring an additional 44,461 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Seres Therapeutics by 221.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 48,013 shares during the last quarter. Hedge funds and other institutional investors own 59.34% of the company's stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.